OTCMKTS:SNPHY Santen Pharmaceutical (SNPHY) Stock Price, News & Analysis $9.54 +0.07 (+0.73%) As of 03:36 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsSEC FilingsShort InterestBuy This Stock About Santen Pharmaceutical Stock (OTCMKTS:SNPHY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Santen Pharmaceutical alerts:Sign Up Key Stats Today's Range$9.54▼$9.5450-Day Range$8.77▼$10.7452-Week Range$8.65▼$13.00Volume376 shsAverage Volume9,927 shsMarket CapitalizationN/AP/E Ratio0.09Dividend Yield506.28%Price TargetN/AConsensus RatingN/A Company OverviewSanten Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension. In addition, it provides cyclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis; and diquafosol sodium for dry eye treatment. Further, the company develops olodaterol hydrochloride, a ß2 receptor agonist that is in phase 1/2a for the treatment of A dry eye treatment dry eye; sirolimus, an ophthalmic suspension which is in phase 2a for the treatment of 4 Fuchs endothelial corneal dystrophy and meibomian gland dysfunction; epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval for the treatment of allergic conjunctivitis; atropine sulfate, a non-selective muscarinic antagonist that is in phase 2/3 clinical trials for myopia treatment; and AFDX0250BS, an selective muscarinic M2 antagonist which is in phase 2a for the treatment of myopia. Additionally, it offers ursodeoxycholic acid that is in phase 2a of clinical trial for the treatment of presbyopia; and oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase 3 for treatment of ptosis. The company was founded in 1890 and is headquartered in Osaka, Japan.Read More… Remove Ads Santen Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreSNPHY MarketRank™: Santen Pharmaceutical scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Santen Pharmaceutical. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Santen Pharmaceutical is 0.09, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.55.Price to Earnings Ratio vs. SectorThe P/E ratio of Santen Pharmaceutical is 0.09, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.42.Read more about Santen Pharmaceutical's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares ShortedShort Interest Ratio / Days to CoverSanten Pharmaceutical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Santen Pharmaceutical has recently decreased by 55.56%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldSanten Pharmaceutical pays a meaningful dividend of 1.47%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthSanten Pharmaceutical does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Santen Pharmaceutical is 46.34%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about Santen Pharmaceutical's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares ShortedShort Interest Ratio / Days to CoverSanten Pharmaceutical has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Santen Pharmaceutical has recently decreased by 55.56%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentSanten Pharmaceutical has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Santen Pharmaceutical this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Santen Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.05% of the stock of Santen Pharmaceutical is held by institutions.Read more about Santen Pharmaceutical's insider trading history. Receive SNPHY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Santen Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address SNPHY Stock News HeadlinesSanten Pharmaceutical to Cancel 5 Million Treasury SharesFebruary 6, 2025 | tipranks.comSanten Pharmaceutical Co. Revises Year-End Dividend ForecastFebruary 6, 2025 | tipranks.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 1, 2025 | Porter & Company (Ad)Santen Pharmaceutical Announces Share Buyback PlanNovember 8, 2024 | markets.businessinsider.comSanten Pharmaceutical Co., Ltd. GAAP EPS of Yen 27.85, revenue of Yen 72.34BAugust 6, 2024 | msn.comHere's what to expect from Santen Pharmaceutical's earnings reportAugust 6, 2024 | markets.businessinsider.comSNPHY Stock Earnings: Santen Pharmaceutical Reported Results for Q4 2023May 17, 2024 | investorplace.comSanten Pharmaceutical earnings preview: what to expectMay 9, 2024 | markets.businessinsider.comSee More Headlines SNPHY Stock Analysis - Frequently Asked Questions How have SNPHY shares performed this year? Santen Pharmaceutical's stock was trading at $10.12 at the beginning of the year. Since then, SNPHY shares have decreased by 5.7% and is now trading at $9.54. View the best growth stocks for 2025 here. How do I buy shares of Santen Pharmaceutical? Shares of SNPHY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today4/01/2025Next Earnings (Estimated)5/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:SNPHY CIK1501108 Webwww.santen.com Phone(167) 664-8621FaxN/AEmployees4,144Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.09 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:SNPHY) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Santen Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Santen Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.